InterVene

InterVene is a clinical-stage medical device company pioneering a novel mechanical thrombectomy system for treating complex venous obstructions, particularly venous in-stent restenosis (ISR) and chronic post-thrombotic occlusions. Its technology targets a large, underserved patient population suffering from post-thrombotic syndrome (PTS), where current interventional strategies like balloon angioplasty and stent relining are often ineffective. Led by a seasoned management team with deep vascular device expertise and backed by venture capital, the company is positioned to reshape the interventional treatment paradigm for these debilitating venous conditions.

First fully integrated mechanical thrombectomy system designed specifically for venous in-stent restenosis (ISR) and chronic, organized thrombotic obstructions in native vessels.

The competitive landscape for dedicated venous mechanical thrombectomy is currently sparse, representing a white space. However, competition exists from off-label use of arterial thrombectomy catheters and the standard-of-care options of balloon angioplasty and stent relining. Larger vascular device companies could enter the space if InterVene validates the market.